Virtus Advisers LLC Invests $1.17 Million in Phibro Animal Health Corporation $PAHC

Key Points

• Virtus Advisers LLC acquired a new stake in Phibro Animal Health Corporation, investing approximately $1.17 million for 54,576 shares, making it the company's 10th largest holding.
• Phibro Animal Health recently declared a quarterly dividend of $0.12 per share, with an expected annualized yield of 1.5% and a payout ratio of 61.54%.
• Several analysts have adjusted their ratings and price targets for Phibro Animal Health, with JPMorgan raising its target from $25.00 to $35.00 while maintaining an "overweight" rating.

Virtus Advisers LLC acquired a new position in Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The firm acquired 54,576 shares of the company's stock, valued at approximately $1,166,000. Phibro Animal Health accounts for 1.5% of Virtus Advisers LLC's investment portfolio, making the stock its 10th biggest holding. Virtus Advisers LLC owned 0.13% of Phibro Animal Health at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Phibro Animal Health in the 4th quarter worth about $29,000. National Bank of Canada FI acquired a new stake in shares of Phibro Animal Health in the first quarter valued at about $30,000. Lazard Asset Management LLC grew its stake in shares of Phibro Animal Health by 2,739.7% in the fourth quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock valued at $34,000 after buying an additional 1,589 shares in the last quarter. Aquatic Capital Management LLC acquired a new stake in Phibro Animal Health during the 4th quarter valued at approximately $69,000. Finally, Virtus Fund Advisers LLC acquired a new stake in Phibro Animal Health during the 4th quarter valued at approximately $69,000. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PAHC. JPMorgan Chase & Co. upgraded Phibro Animal Health from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $25.00 to $35.00 in a research note on Monday, July 7th. Morgan Stanley set a $26.00 target price on Phibro Animal Health and gave the stock an "equal weight" rating in a research report on Wednesday, June 25th. Wall Street Zen upgraded Phibro Animal Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. BNP Paribas upgraded Phibro Animal Health to a "hold" rating in a research report on Monday, June 16th. Finally, BNP Paribas Exane upgraded Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 target price for the company in a research report on Monday, June 16th. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Phibro Animal Health currently has a consensus rating of "Reduce" and an average target price of $24.40.

Phibro Animal Health Stock Performance

PAHC stock traded up $6.26 during trading on Thursday, reaching $38.46. 1,069,800 shares of the company's stock were exchanged, compared to its average volume of 268,053. The company has a quick ratio of 1.23, a current ratio of 2.91 and a debt-to-equity ratio of 2.67. Phibro Animal Health Corporation has a 1-year low of $16.16 and a 1-year high of $38.83. The company's fifty day moving average price is $29.07 and its 200-day moving average price is $24.38. The firm has a market cap of $1.56 billion, a PE ratio of 15.41, a P/E/G ratio of 0.54 and a beta of 0.80.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its quarterly earnings results on Wednesday, August 27th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.52 by $0.05. Phibro Animal Health had a return on equity of 33.03% and a net margin of 3.73%.The company had revenue of $378.70 million during the quarter, compared to analyst estimates of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. On average, research analysts expect that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 24th. Stockholders of record on Wednesday, September 3rd will be issued a $0.12 dividend. The ex-dividend date is Wednesday, September 3rd. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. Phibro Animal Health's dividend payout ratio is 61.54%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.